TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02769650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTO coronary angioplasty
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
Study: NCT01295905

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon B contact lens
Description: Commercially marketed silicone hydrogel, single vision soft contact lens
Study: NCT03949842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol
Description: The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
Study: NCT02787265

Intervention type: DEVICE
Intervention: spinal cord stimulation
Study: NCT00285818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone is a glucocorticoid receptor antagonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo is a capsule without a pharmacological active ingredient
Study: NCT04490239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal heparin sodium (porcine)
Description: Intranasal heparin sodium
Study: NCT03625934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VVX001
Description: 5 s.c. injections of 20 micrograms of VVX001 four weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 s.c. injections of matching Placebo four weeks apart
Study: NCT02542982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Endomed 482; Enraf-Nonius B.V.)
Description: non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (Endomed 482; Enraf-Nonius B.V.)
Description: non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
Study: NCT02590926

Intervention type: PROCEDURE
Intervention: Fractional Flow Reserve, Myocardial
Description: The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
Study: NCT04439344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study: NCT01035580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: all patients received the drug
Study: NCT00532155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel (Taxotere®)
Description: 75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Description: 75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone (pre- and post-medication for docetaxel)
Description: As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (pre- and post-medication for docetaxel)
Description: As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
Study: NCT00402272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study: NCT01485393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: 12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: 12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
Study: NCT03204227

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JEVAX
Description: JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
Study: NCT02769650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medicamentous treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress-MRI
Description: A standard stress-MRI test with adenosine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress-MRI
Description: A standard stress-MRI test with adenosine
Study: NCT02773940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariCore System
Description: Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
Study: NCT01333917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin C3 tablet
Description: 4 grams Curcumin C3 tablet daily x30 days
Study: NCT01876953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02419573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube (King)
Description: In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
Study: NCT04214288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Dosage formulation: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Dosage formulation: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Dosage formulation: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
Study: NCT04323722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Empty Bladder planning CT scan and CBCTs
Description: Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
Study: NCT03205501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-administation of EMI-137
Description: Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
Study: NCT02959840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure Point P6 stimulator
Description: This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
Study: NCT03348488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafiltration dose
Description: Fixed high volume of ultrafiltration over an hour during dialysis
Study: NCT01136928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American ginseng
Description: Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
Study: NCT02853344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT04378127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
Study: NCT03011619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Standard of Care
Description: medication management, group therapy, and individual therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Standard of Care
Description: medication management, group therapy, and individual therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Condition (CBT)
Description: CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
Study: NCT02385370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: 0.1 cc of 0.01% MMC is injected into the tenon.
Study: NCT03392077

Intervention type: PROCEDURE
Intervention: Caesarean section
Description: Caesarean section will be done to deliver the baby

Intervention type: PROCEDURE
Intervention: Caesarean section
Description: Caesarean section will be done to deliver the baby

Intervention type: OTHER
Intervention: cervical dilatation
Description: Cervical dilatation will be done by double gloves digital dilatation postpartum
Study: NCT01512394

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard bowel prep
Description: standard bowel prep

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no bowel prep
Description: no bowel prep
Study: NCT03471754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESA-HB Transcranial Electronic Stimulation Device
Description: Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
Study: NCT01439425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
Study: NCT00961805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance
Description: Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
Study: NCT02824289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safe Workplaces Program
Description: The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
Study: NCT02949271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Programmed Intermittent Epidural Bolus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT04631380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRAYER
Description: THE PRAYER GROUP WILL RECEIVE ABSOLUTELY THE SAME CARE AS THE CONTROL GROUP PLUS PRAYERS
Study: NCT04196348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short BPL RYGB
Description: Alimentary limb (AL) with 120 cm and BPL with 100 cm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long BPL RYGB
Description: AL with 120 cm and BPL with 200 cm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long BPL RYGB
Description: AL with 120 cm and BPL with 200 cm.
Study: NCT01053091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
Study: NCT01599689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirrors Intervention
Description: Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams.
Study: NCT03852524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
Study: NCT02949271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT03852524

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
Study: NCT02697617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01460381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Study: NCT04074551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1701
Description: HCP1701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin and Ezetimibe
Description: Rosuvastatin and Ezetimibe
Study: NCT01386086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
Study: NCT03738657

Intervention type: OTHER
Intervention: Olfactory screening
Description: Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.

Intervention type: OTHER
Intervention: Quantative Gustatory Testing using Taste Strips
Description: Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip.
Study: NCT03303105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125
Description: TEV-48125 will be administered subcutaneously once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125
Description: TEV-48125 will be administered subcutaneously once every 12 weeks.
Study: NCT03610477

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medium chain triglycerides
Description: Gel capsules, each containing 1 gram

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Long chain triglycerides
Description: Gel capsules, each containing 1 gram
Study: NCT00515840

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiotherapist
Description: Physiotherapist administered breathing retraining programme